Plasma levels and diagnostic value of catestatin in patients with heart failure |
| |
| Institution: | 1. UCLA David Geffen School of Medicine, Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, Los Angeles, CA 90095, United States;2. UCLA David Geffen School of Medicine, Department of Medicine, Division of Geriatrics, Los Angeles, CA 90095, United States;2. University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom;3. Department of Electrophysiology, Dresden University—Heart Center, Dresden, Germany;4. 3rd Department of Cardiology, Department of Cardiovascular Diseases, Silesian Center for Heart Diseases, Zabrze, Poland;1. Department of Pathophysiology, University of Split School of Medicine, Split, Croatia;2. University Hospital of Split, Split, Croatia;3. Department of Cardiology, University Hospital of Split, Split, Croatia;4. Department of Internal Medicine, University of Split School of Medicine, Split, Croatia;5. Working Group on Heart Failure of Croatian Cardiac Society, Croatia;1. Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran;2. Student’s Scientific Research Center, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran;1. Assistant Professor, Department of Removable Prosthodontics, The Nippon Dental University School of Life Dentistry at Niigata, Japan; The Nippon Dental University Niigata Hospital, Japan;2. Professor, Department of Removable Prosthodontics, The Nippon Dental University School of Life Dentistry at Niigata, Japan; The Nippon Dental University Niigata Hospital, Japan;3. Assistant Professor, Dry Mouth Clinic, Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry at Niigata, Japan; The Nippon Dental University Niigata Hospital, Japan;4. Lecturer, Department of Removable Prosthodontics, The Nippon Dental University School of Life Dentistry at Niigata, Japan; The Nippon Dental University Niigata Hospital, Japan;5. Lecturer, Comprehensive Dental Care, The Nippon Dental University School of Life Dentistry at Niigata, Japan; The Nippon Dental University Niigata Hospital, Japan;6. Professor, Department of Biochemistry, The Nippon Dental University School of Life Dentistry at Niigata, Japan; The Nippon Dental University Niigata Hospital, Japan |
| |
| Abstract: | Catestatin (CST) is an endogenous neuropeptide with multiple cardiovascular activities. The study is to investigate circulating CST levels in heart failure (HF) patients and to evaluate the role of CST as a biomarker for HF. Plasma CST concentrations were measured by enzyme-linked immunosorbent assay in 228 HF patients and 172 controls. Plasma CST gradually increased in patients from NYHA class I to class IV. No significant differences in CST were found among NYHA I, NYHA II patients and controls. Plasma CST in NYHA III and IV patients was higher compared to other groups. Plasma CST levels in HF patients after treatment were similar to admission, but still higher than controls. In a subgroup analysis among the patients with NYHA class III or IV, patients with ischemic etiology had significantly higher CST. Plasma CST levels were similar between patients with preserved and reduced ejection fraction. Multivariable analysis showed that NYHA classes, the etiology of HF (ischemic or not) and estimated glomerular filtration rate independently predicted plasma LogCST levels (P < 0.05). The area under ROC for CST and BNP in moderate to severe HF diagnosis was 0.626 and 0.831, respectively, combining CST and BNP did not improve the accuracy. |
| |
| Keywords: | Catestatin Heart failure Neuroendocrine Biomarker |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
